US20200325440A1 - Bacterial strains capable of metabolizing oxalates - Google Patents

Bacterial strains capable of metabolizing oxalates Download PDF

Info

Publication number
US20200325440A1
US20200325440A1 US16/861,136 US202016861136A US2020325440A1 US 20200325440 A1 US20200325440 A1 US 20200325440A1 US 202016861136 A US202016861136 A US 202016861136A US 2020325440 A1 US2020325440 A1 US 2020325440A1
Authority
US
United States
Prior art keywords
dsm
paracasei
bacterial
medical device
oligosaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/861,136
Inventor
Giovanni Mogna
Gian Paolo Strozzi
Luca Mogna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probiotical SpA
Original Assignee
Probiotical SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiotical SpA filed Critical Probiotical SpA
Priority to US16/861,136 priority Critical patent/US20200325440A1/en
Assigned to PROBIOTICAL S.P.A. reassignment PROBIOTICAL S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOGNA, GIOVANNI, MOGNA, LUCA, STROZZI, GIAN PAOLO
Publication of US20200325440A1 publication Critical patent/US20200325440A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C12R1/225—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • the present invention relates to a selection of lactic bacterial strains and bifidobacteria of human intestinal origin capable of metabolizing oxalic acid and/or the salts thereof (oxalates). Moreover, the present invention relates to a food composition or supplement product or medical device or pharmaceutical composition containing said bacterial strains.
  • Oxalate (salt of oxalic acid) is an ubiquitous compound in the plant kingdom, widely present in all human diets. The daily intake ranges from 70 to 920 mg (average 495 mg ⁇ 5.6 mM), but these values are easily exceeded in the diets of vegetarians.
  • Oxalic acid (dicarboxylic acid) is one of the most highly oxidized organic compounds and thus acts as a powerful chelating agent for cations, in particular the ion Ca2+. Because of this property, the salts of oxalic acid (oxalates) are of very little use in catabolic processes and energy production. Moreover, oxalic acid is toxic for the majority of living beings and particularly for mammals.
  • oxalic acid and oxalates in man can trigger and exacerbate a series of pathological conditions, among which we shall mention hyperoxaluria, urolithiasis, kidney failure, cardiomyopathies and other cardiac disorders.
  • oxalic acid combines with calcium to form the corresponding calcium oxalate, an insoluble salt which is responsible for over 70% of the kidney stones diagnosed.
  • oxalic acid is a powerful inflammatory agent affecting the intestinal mucosa. Therefore, an excess presence of this acid in the lumen can compromise the natural barrier function of the epithelium by altering its permeability and consequently provoking an increased absorption of oxalate.
  • the colon is the main site of absorption of oxalate, with an intake of 3-5% in normal physiological conditions. Reducing the oxalate in the intestinal lumen could therefore contribute to reducing absorption. This would then lead to a decrease in the concentration of oxalates in plasma and in urine, thus reducing the hazardousness thereof.
  • Diverticulosis also known as “diverticular disease” is a medical condition characterized by diverticula in the colon; these are eversions of the mucosa and submucosa of the colon through areas of relative weakness of the muscular layer in the wall of the colon. Diverticula are decidedly more common in the sigmoid colon, which is a portion of the intestine characterized by greater pressure, a factor facilitating the formation of diverticula. Diverticulitis is a pathology of the digestive tract, characterized by the inflammation of one or more diverticula. The majority of cases of diverticulitis are localized in the colon (in particular the descending and sigmoid colon).
  • oxalates in the intestinal lumen, plasma and urine in such a way as to avoid the complications connected with high values of oxalates, such as, for example, hyperoxaluria, urolithiasis, kidney failure, cardiomyopathies and other cardiac disorders, kidney stones, diverticulosis and diverticulitis.
  • the Applicant has provided an answer to the above-mentioned needs following an intense activity of research, at the end of which it identified, from a highly vast set of strains, a selection of bacterial strains belonging to the genera Lactobacillus and Bifidobacterium ; said strains exhibit a marked ability to quantitatively degrade oxalates.
  • the selected strains show the ability to use oxalate as a source of energy, removing it from the environment in which said oxalate was originally to be found. Therefore, the selected strains are capable of degrading oxalates.
  • the subject matter of the present invention relates to a bacterial strain belonging to the genera Lactobacillus and Bifidobacterium and having the ability to degrade oxalates, as disclosed in the appended independent claim.
  • the subject matter of the present invention also relates to a food composition or supplement product or medical device or pharmaceutical composition containing said bacterial strains, as disclosed in the appended independent claim.
  • FIG. 1A-B shows a comparison between the chromatogram for a culture medium containing 5 mM of oxalate before (in FIG. 1A ) and after (in FIG. 1B ) SPE purification.
  • FIG. 2 shows a chromatogram for a culture medium containing 5 mM of oxalate (positive reference).
  • FIG. 3 shows a chromatogram for the bacterial strain B. breve BR03 DSM 16604.
  • FIG. 4 shows a chromatogram for the bacterial strain L. paracasei spp. paracasei LPC09 DSM 24243.
  • the Applicant has developed a method capable of identifying and quantifying the oxalate degrading ability of cultures of strains belonging to the genera Lactobacillus and Bifidobacterium.
  • L. paracasei spp. paracasei LPC 09 deposited by the company Probiotical SpA of Novara (Italy) on 23 Nov. 2010, with deposit number DSM 24243.
  • L. gasseri LGS 01 deposited by the company Probiotical SpA of Novara (Italy) on 24 May 2006, with deposit number DSM 18299.
  • L. gasseri LGS 02 deposited by the company Probiotical SpA of Novara (Italy) on 24 May 2006, with deposit number DSM 18300.
  • L. acidophilus LA 07 deposited by the company Probiotical SpA of Novara (Italy) on 23 Nov. 2010, with deposit number DSM 24303.
  • L. acidophilus LA 02 deposited by the company Probiotical SpA of Novara (Italy) on 6 Aug. 2008, with deposit number DSM 21717.
  • L. plantarum LP 01 deposited by the company Mofin Srl of Novara (Italy) with the Depositary Institution BCCM-LMG (Belgium) on 16 Oct. 2001, with deposit number LMG-P-21021,
  • L. reuteri LRE 03 deposited by the company Probiotical SpA of Novara (Italy) on 5 Aug. 2010, with deposit number DSM 23879.
  • L. reuteri LRE 02 deposited by the company Probiotical SpA of Novara (Italy) on 5 Aug.
  • rhamnosus LR 06 deposited by the company Probiotical SpA of Novara (Italy) on 14 Nov. 2008, with deposit number DSM 21981.
  • B. lactis BA 05 deposited by the company Probiotical SpA of Novara (Italy) on 15 Jun. 2006, with deposit number DSM 18352.
  • L. casei spp. rhamnosus LR 04 deposited by the company Probiotical SpA of Novara (Italy) on 20 Jul. 2004, with deposit number DSM 16605.
  • the composition comprises or, alternatively, consists of at least one strain selected from among those indicated above by (i) to (xv); preferably the strains are selected from among those indicated above by (i) to (viii).
  • bacteria strain means the live and/or dead cells and/or parts, components/derivatives and/or enzymes thereof.
  • the selected bacterial strains belong to the genus Lactobacillus and have an ability to degrade and use oxalate as a source of energy in an amount greater than 50%.
  • said ability is greater than 60%.
  • said ability is greater than 70%.
  • the selected bacterial strains belong to the species Lactobacillus paracasei .
  • a preferred strain is L. paracasei spp. paracasei LPC 09 DSM 24243.
  • the selected bacterial strains belong to the species Lactobacillus gasseri.
  • Several preferred strains are selected from the group comprising or, alternatively, consisting of L. gasseri LGS 01 DSM 18299 and L. gasseri LGS 02 DSM 18300.
  • the selected bacterial strains belong to the species Lactobacillus acidophilus .
  • Several preferred strains are selected from the group comprising or, alternatively, consisting of L. acidophilus LA02 DSM 21717 and L. acidophilus LA 07 DSM 24303.
  • a composition in accordance with the present invention comprises at least one bacterial strain, for use in the treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis.
  • the composition can be a food composition or supplement product or medical device or pharmaceutical composition.
  • composition for use in the treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis comprises or, alternatively, consists of at least two strains selected from among those indicated above by (i) to (xv), preferably the strains are selected from among those indicated above by (i) to (viii).
  • composition for use in the treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis comprises or, alternatively, consists of at least two strains selected from among those indicated above by (i) to (v).
  • composition for use in the treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis comprises or, alternatively, consists of:
  • compositions can further comprise fructo-oligosaccharides (FOS) and/or inulin.
  • Fructo-oligosaccharides (FOS) and/or inulin are included in an amount comprised from 1 to 30% by weight, relative to the weight of the composition, preferably from 3 to 15%, even more preferably from 5 to 10% by weight.
  • the subject matter of the present invention relates to a bacterial strain belonging to the species Lactobacillus paracasei or Lactobacillus gasseri and which is capable of degrading oxalic acid and/or the salts thereof in an amount greater than 60%.
  • Said strain is capable of degrading oxalic acid and/or the salts thereof in an amount greater than 70%.
  • Said strain belonging to the species Lactobacillus paracasei is L. paracasei spp. paracasei LPC 09 DSM 24243.
  • Said strain belonging to the species Lactobacillus gasseriis selected from the group consisting of the strain L. gasseri LGS 01 DSM 18299 and the strain L. gasseri LGS 02 DSM 18300.
  • the subject matter of the present invention relates to a food composition or supplement product or medical device or pharmaceutical composition comprising a bacterial composition; said bacterial composition comprises at least one bacterial strain as described above, for use in the preventive and curative treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis.
  • Said bacterial composition comprises the strain L. paracasei spp. paracasei LPC 09 DSM 24243.
  • Said bacterial composition comprises the strain L. gasseri LGS 01 DSM 18299 and the strain L. gasseri LGS 02 DSM 18300.
  • Said bacterial composition further comprises the strain L. acidophilus LA02 DSM 21717 and the strain L.
  • Said bacterial composition consists of L. paracasei spp. paracasei LPC 09 DSM 24243 , L. acidophilus LA02 DSM 21717 and/or L. acidophilus LA 07 DSM 24303.
  • Said composition further comprises fructo-oligosaccharides and/or inulin.
  • strains belonging to the genera Bifidobacterium and Lactobacillus were studied; they came from the internal strain collection of the company Probiotical SpA of Novara and international collections such as, for example, the DSMZ—Germany, or were found in the literature.
  • the selected strains are shown in Table 1, which shows the percentage of oxalate degradation by the bacterial strains tested. The experiment was conducted using a culture medium containing 5 mM ammonium oxalate.
  • the bacterial strains (i) to (v), (vii) to (x) and (xii) to (xv) listed in Table 1 were deposited by the company Probiotical SpA of Novara (Italy).
  • Strain (vi) was deposited by the company Mofin Srl of Novara (Italy).
  • Strain (xi) is available from the ATCC collection. All strains are available and accessible to the public under the conditions established by the Budapest Treaty.
  • the preparation of the strains to be submitted to analysis consisted in a series of three sequential subcultures in MRS broth (+1% cys-HCl, anaerobiosis, for the bifids) incubated at 37° C. until adequate growth was reached.
  • This culture strategy enables complete activation of the strain.
  • the strains were subsequently inoculated at the same percentage of inoculum (2%) in an experimental medium, specifically conceived to ensure maximum growth of lactobacilli and bifidobacteria, supplemented with 5 mM ammonium oxalate (amount equal to the average daily intake of oxalic acid).
  • the cultures thus prepared were incubated for 24 hours at 37° C.
  • the broth cultures were centrifuged and the supernatant was filtered through a 0.22 ⁇ m filter.
  • HPLC injection of the samples brought to light an unclear chromatographic profile.
  • the chromatographic peak of oxalic acid appeared to overlap the glucose peak present in the samples.
  • the samples were purified using SPE (solid phase extraction) columns specific for organic acids.
  • the protocol for purification by SPE columns required an optimization step in order to obtain the best final yield.
  • different reagents were used in relation to the column conditioning step and final elution of the analyte.
  • This solid-phase purification made it possible to obtain a distinctly cleaner chromatographic peak of oxalic acid, as can be seen in FIG. 1 A-B.
  • the protocol used was the following
  • Type of SPE column Phenomenex Strata-XA Activation: 1 ml of methanol Conditioning: 2 ml of sodium formiate 20 mM Sample loading: 1 ml sample Washing of impurities: 1 ml ammonium acetate 25 mM+1 ml methanol
  • the amount of oxalate degraded by each individual strain was analyzed by HPLC, calculating the difference between the concentration of oxalate present in the culture medium (5 mM) at T0 (before fermentation) and the residual concentration after growth of the microorganism.
  • the results of the individual strains are expressed as percentages, considering the concentration of oxalate at T0 to be 100.
  • the result of the strain L. paracasei spp. paracasei LPC 09 DSM 24243, equal to around 70% indicates that the latter is able to use an amount of oxalate equal to around 3.5 mM of oxalate (70% of 5 mM).
  • the HPLC protocol used was the following:
  • Type of column Phenomenex Hydro-RP 250 ⁇ 4.6 mm
  • Type of detector UV-Vis with reading at 220 nm
  • Elution flow rate 0.7 ml/min
  • Injection volume 20 ⁇ l
  • Column temperature 30° C.
  • Type of elution isocratic Mobile phase: 20 mM Potassium phosphate pH 2.0
  • the bacterial strains belonging to the genus Lactobacillus which showed a high degradation activity towards oxalic acid are the ones indicated above by (i) to (v).
  • the strain LPC09 was reactivated prior to the experiment by subculture in MRS and incubated under aerobiosis at 37° C. The reactivation steps were repeated three times prior to the experiment with overnight incubation. At the end of the third reactivation step, the cells were pelleted, washed with sterile water and resuspended before being inoculated into the culture media supplemented with fibre.
  • the media used were based on sugar-free MRS (carbon sources), supplemented respectively with:
  • the final concentration of carbon sources for all media was 20 g/l.
  • the media thus prepared were then inoculated with the strain LPC09, at a percentage of 4%, and incubated at 37° C. under aerobiosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A selection of strains of lactic bacteria and bifidobacteria of human intestinal origin capable of metabolizing oxalates is described. Moreover, a food composition or supplement product or pharmaceutical composition containing said bacterial strains is also described.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application is a divisional application of U.S. application Ser. No. 14/116,996, filed on Dec. 18, 2013 incorporated herein by reference, which, in turn, is the US national stage of International Patent Application PCT/IB2012/000895 filed on May 9, 2012 which, in turn, claims priority to Italian Patent Application MI2011A000791 filed on May 9, 2011.
  • The present invention relates to a selection of lactic bacterial strains and bifidobacteria of human intestinal origin capable of metabolizing oxalic acid and/or the salts thereof (oxalates). Moreover, the present invention relates to a food composition or supplement product or medical device or pharmaceutical composition containing said bacterial strains.
  • Oxalate (salt of oxalic acid) is an ubiquitous compound in the plant kingdom, widely present in all human diets. The daily intake ranges from 70 to 920 mg (average 495 mg˜5.6 mM), but these values are easily exceeded in the diets of vegetarians. Oxalic acid (dicarboxylic acid) is one of the most highly oxidized organic compounds and thus acts as a powerful chelating agent for cations, in particular the ion Ca2+. Because of this property, the salts of oxalic acid (oxalates) are of very little use in catabolic processes and energy production. Moreover, oxalic acid is toxic for the majority of living beings and particularly for mammals.
  • For this reason, the accumulation of oxalic acid and oxalates in man can trigger and exacerbate a series of pathological conditions, among which we shall mention hyperoxaluria, urolithiasis, kidney failure, cardiomyopathies and other cardiac disorders. In particular, oxalic acid combines with calcium to form the corresponding calcium oxalate, an insoluble salt which is responsible for over 70% of the kidney stones diagnosed. Moreover, oxalic acid is a powerful inflammatory agent affecting the intestinal mucosa. Therefore, an excess presence of this acid in the lumen can compromise the natural barrier function of the epithelium by altering its permeability and consequently provoking an increased absorption of oxalate. In particular, the colon is the main site of absorption of oxalate, with an intake of 3-5% in normal physiological conditions. Reducing the oxalate in the intestinal lumen could therefore contribute to reducing absorption. This would then lead to a decrease in the concentration of oxalates in plasma and in urine, thus reducing the hazardousness thereof.
  • Moreover, high levels of oxalates in the blood can lead to diverticulosis or diverticulitis. Diverticulosis, also known as “diverticular disease”, is a medical condition characterized by diverticula in the colon; these are eversions of the mucosa and submucosa of the colon through areas of relative weakness of the muscular layer in the wall of the colon. Diverticula are decidedly more common in the sigmoid colon, which is a portion of the intestine characterized by greater pressure, a factor facilitating the formation of diverticula. Diverticulitis is a pathology of the digestive tract, characterized by the inflammation of one or more diverticula. The majority of cases of diverticulitis are localized in the colon (in particular the descending and sigmoid colon).
  • Therefore, it is important to be able to reduce the amount of oxalates in the intestinal lumen, plasma and urine in such a way as to avoid the complications connected with high values of oxalates, such as, for example, hyperoxaluria, urolithiasis, kidney failure, cardiomyopathies and other cardiac disorders, kidney stones, diverticulosis and diverticulitis.
  • In particular, it is desirable to be able to reduce the levels of oxalate in the urine of two types of subjects:
      • Hyperoxaluric subjects who do not tend toward a diet with a high oxalate content.
      • Normooxaluric subjects who tend toward to a diet with a high oxalate content.
  • The Applicant has provided an answer to the above-mentioned needs following an intense activity of research, at the end of which it identified, from a highly vast set of strains, a selection of bacterial strains belonging to the genera Lactobacillus and Bifidobacterium; said strains exhibit a marked ability to quantitatively degrade oxalates. The selected strains show the ability to use oxalate as a source of energy, removing it from the environment in which said oxalate was originally to be found. Therefore, the selected strains are capable of degrading oxalates.
  • The subject matter of the present invention relates to a bacterial strain belonging to the genera Lactobacillus and Bifidobacterium and having the ability to degrade oxalates, as disclosed in the appended independent claim.
  • The subject matter of the present invention also relates to a food composition or supplement product or medical device or pharmaceutical composition containing said bacterial strains, as disclosed in the appended independent claim.
  • Preferred embodiments of the present invention will be illustrated in the detailed description that follows.
  • FIG. 1A-B shows a comparison between the chromatogram for a culture medium containing 5 mM of oxalate before (in FIG. 1A) and after (in FIG. 1B) SPE purification.
  • FIG. 2 shows a chromatogram for a culture medium containing 5 mM of oxalate (positive reference).
  • FIG. 3 shows a chromatogram for the bacterial strain B. breve BR03 DSM 16604.
  • FIG. 4 shows a chromatogram for the bacterial strain L. paracasei spp. paracasei LPC09 DSM 24243.
  • FIG. 5 shows acidification curves (pH value) obtained as a function of time (T=0, 3, 6, 8 and 10 hours) when the strain L. paracasei spp. paracasei LPC 09 DSM 24243 was made to grow in a sugar-free MRS culture medium (carbon source), to which other carbon sources (fibres) were respectively added.
    •
  • The Applicant has developed a method capable of identifying and quantifying the oxalate degrading ability of cultures of strains belonging to the genera Lactobacillus and Bifidobacterium.
  • The Applicant has found that the following bacterial strains have a demonstrated ability to use oxalates as an energy source:
  • (i) L. paracasei spp. paracasei LPC 09, deposited by the company Probiotical SpA of Novara (Italy) on 23 Nov. 2010, with deposit number DSM 24243.
    (ii) L. gasseri LGS 01, deposited by the company Probiotical SpA of Novara (Italy) on 24 May 2006, with deposit number DSM 18299.
    (iii) L. gasseri LGS 02, deposited by the company Probiotical SpA of Novara (Italy) on 24 May 2006, with deposit number DSM 18300.
    (iv) L. acidophilus LA 07, deposited by the company Probiotical SpA of Novara (Italy) on 23 Nov. 2010, with deposit number DSM 24303.
    (v) L. acidophilus LA 02, deposited by the company Probiotical SpA of Novara (Italy) on 6 Aug. 2008, with deposit number DSM 21717.
    (vi) L. plantarum LP 01, deposited by the company Mofin Srl of Novara (Italy) with the Depositary Institution BCCM-LMG (Belgium) on 16 Oct. 2001, with deposit number LMG-P-21021,
    (vii) L. reuteri LRE 03, deposited by the company Probiotical SpA of Novara (Italy) on 5 Aug. 2010, with deposit number DSM 23879.
    (viii) L. reuteri LRE 02, deposited by the company Probiotical SpA of Novara (Italy) on 5 Aug. 2010, with deposit number DSM 23878.
    (ix) B. breve BR 03, deposited by the company Probiotical SpA of Novara (Italy) on 16 Jul. 2004, with deposit number DSM 16604.
    (x) B. longum BL 03, deposited by the company Probiotical SpA of Novara (Italy) on 20 Jul. 2004, with deposit number DSM 16603.
    (xi) L. rhamnosus GG, ATCC 53103, available in the ATCC public collection.
    (xii) L. reuteri LRE 04, deposited by the company Probiotical SpA of Novara (Italy) on 5 Aug. 2010, with deposit number DSM 23880.
    (xiii) L. rhamnosus LR 06, deposited by the company Probiotical SpA of Novara (Italy) on 14 Nov. 2008, with deposit number DSM 21981.
    (xiv) B. lactis BA 05, deposited by the company Probiotical SpA of Novara (Italy) on 15 Jun. 2006, with deposit number DSM 18352.
    (xv) L. casei spp. rhamnosus LR 04, deposited by the company Probiotical SpA of Novara (Italy) on 20 Jul. 2004, with deposit number DSM 16605.
  • In a preferred embodiment, the composition comprises or, alternatively, consists of at least one strain selected from among those indicated above by (i) to (xv); preferably the strains are selected from among those indicated above by (i) to (viii).
  • In the context of the present invention, “bacterial strain” means the live and/or dead cells and/or parts, components/derivatives and/or enzymes thereof.
  • The selected bacterial strains belong to the genus Lactobacillus and have an ability to degrade and use oxalate as a source of energy in an amount greater than 50%. Advantageously, said ability is greater than 60%. Advantageously, said ability is greater than 70%.
  • The selected bacterial strains belong to the species Lactobacillus paracasei. A preferred strain is L. paracasei spp. paracasei LPC 09 DSM 24243.
  • The selected bacterial strains belong to the species Lactobacillus gasseri. Several preferred strains are selected from the group comprising or, alternatively, consisting of L. gasseri LGS 01 DSM 18299 and L. gasseri LGS 02 DSM 18300.
  • The selected bacterial strains belong to the species Lactobacillus acidophilus. Several preferred strains are selected from the group comprising or, alternatively, consisting of L. acidophilus LA02 DSM 21717 and L. acidophilus LA 07 DSM 24303. A composition in accordance with the present invention comprises at least one bacterial strain, for use in the treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis.
  • The composition can be a food composition or supplement product or medical device or pharmaceutical composition.
  • The composition for use in the treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis comprises or, alternatively, consists of at least two strains selected from among those indicated above by (i) to (xv), preferably the strains are selected from among those indicated above by (i) to (viii).
  • The composition for use in the treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis comprises or, alternatively, consists of at least two strains selected from among those indicated above by (i) to (v).
  • The composition for use in the treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis comprises or, alternatively, consists of:
      • (a) L. paracasei spp. paracasei LPC 09-DSM 24243; or
      • (b) L. paracasei spp. paracasei LPC 09-DSM 24243 and L. gasseri LGS 01-DSM 18299; or
      • (c) L. paracasei spp. paracasei LPC 09-DSM 24243 and L. gasseri LGS 02-DSM 18300; or
      • (d) L. paracasei spp. paracasei LPC 09-DSM 24243, L. gasseri LGS 01-DSM 18299 and L. gasseri LGS 02-DSM 18300; or
      • (e) L. paracasei spp. paracasei LPC 09-DSM 24243, L. gasseri LGS 01-DSM 18299, L. gasseri LGS 02-DSM 18300 and L. acidophilus LA 07-DSM 24303; or
      • (f) L. paracasei spp. paracasei LPC 09-DSM 24243, L. gasseri LGS 01-DSM 18299, L. gasseri LGS 02-DSM 18300 and L. acidophilus LA 02-DSM 21717; or
      • (g) L. paracasei spp. paracasei LPC 09-DSM 24243, L. gasseri LGS 01-DSM 18299, L. gasseri LGS 02-DSM 18300, L. acidophilus LA 07-DSM 24303 and L. acidophilus LA 02-DSM 21717.
  • All of the above-described compositions, and particularly the compositions (a) to (g) listed above, can further comprise fructo-oligosaccharides (FOS) and/or inulin. Fructo-oligosaccharides (FOS) and/or inulin are included in an amount comprised from 1 to 30% by weight, relative to the weight of the composition, preferably from 3 to 15%, even more preferably from 5 to 10% by weight.
  • The subject matter of the present invention relates to a bacterial strain belonging to the species Lactobacillus paracasei or Lactobacillus gasseri and which is capable of degrading oxalic acid and/or the salts thereof in an amount greater than 60%. Said strain is capable of degrading oxalic acid and/or the salts thereof in an amount greater than 70%. Said strain belonging to the species Lactobacillus paracasei is L. paracasei spp. paracasei LPC 09 DSM 24243. Said strain belonging to the species Lactobacillus gasseriis selected from the group comprising the strain L. gasseri LGS 01 DSM 18299 and the strain L. gasseri LGS 02 DSM 18300. Said strain belonging to the species Lactobacillus gasseriis selected from the group consisting of the strain L. gasseri LGS 01 DSM 18299 and the strain L. gasseri LGS 02 DSM 18300.
  • The subject matter of the present invention relates to a food composition or supplement product or medical device or pharmaceutical composition comprising a bacterial composition; said bacterial composition comprises at least one bacterial strain as described above, for use in the preventive and curative treatment of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis. Said bacterial composition comprises the strain L. paracasei spp. paracasei LPC 09 DSM 24243. Said bacterial composition comprises the strain L. gasseri LGS 01 DSM 18299 and the strain L. gasseri LGS 02 DSM 18300. Said bacterial composition further comprises the strain L. acidophilus LA02 DSM 21717 and the strain L. acidophilus LA 07 DSM 24303. Said bacterial composition consists of L. paracasei spp. paracasei LPC 09 DSM 24243, L. acidophilus LA02 DSM 21717 and/or L. acidophilus LA 07 DSM 24303. Said composition further comprises fructo-oligosaccharides and/or inulin.
    • EXPERIMENTAL PART 1. Bacterial Strains Analyzed
  • About 70 strains belonging to the genera Bifidobacterium and Lactobacillus were studied; they came from the internal strain collection of the company Probiotical SpA of Novara and international collections such as, for example, the DSMZ—Germany, or were found in the literature. The selected strains are shown in Table 1, which shows the percentage of oxalate degradation by the bacterial strains tested. The experiment was conducted using a culture medium containing 5 mM ammonium oxalate.
  • TABLE 1
    %
    Deposit No. Species/strain Degradation
    DSM
    24243 L. paracasei LPC 09 73.50
    DSM 18299 L. gasseri LGS 01 73.40
    DSM 18300 L. gasseri LGS 02 71.20
    DSM 24303 L. acidophilus LA 07 59.25
    DSM21717 L. acidophilus LA 02 56.35
    LMG P-21021 L. plantarum LP 01 40.31
    DSM 23879 L. reuteri LRE 03 33.86
    DSM 23878 L. reuteri LRE 02 31.42
    DSM 16604 B. breve BR 03 28.16
    DSM 16603 B. longum BL 03 25.29
    ATCC 53103 L. rhamnosus GG 23.59
    DSM 23880 L. reuteri LRE 04 16.79
    DSM 21981 L. rhamnosus LR 06 15.70
    DSM 18352 B. lactis BA 05 15.45
    DSM 16605 L. rhamnosus LR 04 12.89
  • The bacterial strains (i) to (v), (vii) to (x) and (xii) to (xv) listed in Table 1 were deposited by the company Probiotical SpA of Novara (Italy). Strain (vi) was deposited by the company Mofin Srl of Novara (Italy). Strain (xi) is available from the ATCC collection. All strains are available and accessible to the public under the conditions established by the Budapest Treaty.
    • 2. Culture Conditions Adopted
  • The preparation of the strains to be submitted to analysis consisted in a series of three sequential subcultures in MRS broth (+1% cys-HCl, anaerobiosis, for the bifids) incubated at 37° C. until adequate growth was reached. This culture strategy enables complete activation of the strain. The strains were subsequently inoculated at the same percentage of inoculum (2%) in an experimental medium, specifically conceived to ensure maximum growth of lactobacilli and bifidobacteria, supplemented with 5 mM ammonium oxalate (amount equal to the average daily intake of oxalic acid). The cultures thus prepared were incubated for 24 hours at 37° C.
    • 3. SPE (Solid Phase Extraction) Purification of the Samples
  • At the end of the incubation period, the broth cultures were centrifuged and the supernatant was filtered through a 0.22 μm filter. HPLC injection of the samples brought to light an unclear chromatographic profile. In particular, the chromatographic peak of oxalic acid appeared to overlap the glucose peak present in the samples. In order to remedy the aforesaid problem, the samples were purified using SPE (solid phase extraction) columns specific for organic acids.
  • The protocol for purification by SPE columns required an optimization step in order to obtain the best final yield. In particular, different reagents were used in relation to the column conditioning step and final elution of the analyte. This solid-phase purification made it possible to obtain a distinctly cleaner chromatographic peak of oxalic acid, as can be seen in FIG. 1 A-B. The protocol used was the following
  • Type of SPE column: Phenomenex Strata-XA
    Activation: 1 ml of methanol
    Conditioning: 2 ml of sodium formiate 20 mM
    Sample loading: 1 ml sample
    Washing of impurities: 1 ml ammonium acetate 25 mM+1 ml methanol
    • Elution: 2×500 μl HCl 1 M+2×500 μl HCl 3 M 4. HPLC Analysis
  • The amount of oxalate degraded by each individual strain was analyzed by HPLC, calculating the difference between the concentration of oxalate present in the culture medium (5 mM) at T0 (before fermentation) and the residual concentration after growth of the microorganism. The results of the individual strains are expressed as percentages, considering the concentration of oxalate at T0 to be 100. For example, the result of the strain L. paracasei spp. paracasei LPC 09 DSM 24243, equal to around 70%, indicates that the latter is able to use an amount of oxalate equal to around 3.5 mM of oxalate (70% of 5 mM). The HPLC protocol used was the following:
  • Type of column: Phenomenex Hydro-RP 250×4.6 mm
    Type of detector: UV-Vis with reading at 220 nm
    Elution flow rate: 0.7 ml/min
    Injection volume: 20 μl
    Column temperature: 30° C.
    Type of elution: isocratic
    Mobile phase: 20 mM Potassium phosphate pH 2.0
  • The bacterial strains belonging to the genus Lactobacillus which showed a high degradation activity towards oxalic acid are the ones indicated above by (i) to (v).
  • A. Determination of the Acidification Curves for the Strain L. paracasei Spp. Paracasei LPC 09 DSM 24243.
  • The strain LPC09 was reactivated prior to the experiment by subculture in MRS and incubated under aerobiosis at 37° C. The reactivation steps were repeated three times prior to the experiment with overnight incubation. At the end of the third reactivation step, the cells were pelleted, washed with sterile water and resuspended before being inoculated into the culture media supplemented with fibre. The media used were based on sugar-free MRS (carbon sources), supplemented respectively with:
      • Glucose (solution sterilized by heat treatment, 121° C. 15′), control medium.
      • Fructo-oligosaccharides—FOS (solution sterilized by filtration, 0.20 μl filter).
      • GOS-GI, —Galacto-oligosaccharides with glucose residual (solution sterilized by filtration, 0.20 μl filter).
      • GOS-Gal, —Galacto-oligosaccharides with galactose residual (solution sterilized by filtration, 0.20 μl filter).
      • XOS, —xylo-oligosaccharides (solution sterilized by filtration, 0.20 μl filter).
      • Larex, —larch fibre (solution sterilized by heat treatment, 121° C. 15′).
      • Inulin (solution sterilized by heat treatment, 121° C. 15′).
  • The final concentration of carbon sources for all media was 20 g/l.
  • The media thus prepared were then inoculated with the strain LPC09, at a percentage of 4%, and incubated at 37° C. under aerobiosis.
  • At time 0 and at 3, 6, 8 and 10 hours, pH measurements were made in order to construct the acidification curves shown in the graph of FIG. 5.
  • Table 2 shows the acidification curves (pH value) obtained as a function of time (T=0, 3, 6, 8 and 10 hours) when the strain the L. paracasei spp. paracasei LPC 09 DSM 24243 was made to grow in a culture medium as described above.
  • TABLE 2
    0 3 6 8 10
    LPC09 Glu 6.46 5.84 4.65 4.24 4.03
    Fos 6.48 6.02 5.57 4.62 4.13
    Xos 6.47 5.98 5.83 5.76 5.73
    Gos-gal 6.48 6.03 6.02 6.09 6.14
    Gos-glu 6.49 5.9 5.5 5.14 5.09
    Inu 6.5 5.98 4.96 4.3 4.03
    Lar 6.43 5.93 5.95 5.99 6.03

Claims (9)

1.-5. (canceled)
6. A food composition or supplement product or medical device or pharmaceutical composition comprising at least one bacterial strain L. paracasei spp. paracasei LPC 09 DSM 24243 and a fibre selected from the group consisting of fructo-oligosaccharides (FOS), inulin, xylo-oligosaccharides (XOS), and galacto-oligosaccharides with galactose residual (GOS-Gal in an effective amount for preventive and/or curative treatment of at least one of hyperoxaluria, urolithiasis, kidney failure, cardiopathies, kidney stones, diverticulosis and diverticulitis.
7. (canceled)
8. The food composition or supplement product or medical device or pharmaceutical composition according to claim 6, wherein said bacterial composition further comprises the bacterial strain L. gasseri LGS 01 DSM 18299 and the bacterial strain L. gasseri LGS 02 DSM 18300.
9. The food composition or supplement product or medical device or pharmaceutical composition according to claim 6, wherein said bacterial composition further comprises the bacterial strain L. acidophilus LA02 DSM 21717 and the bacterial strain L. acidophilus LA 07 DSM 24303.
10. The food composition or supplement product or medical device or pharmaceutical composition according to claim 6, wherein said bacterial composition consists of L. paracasei spp. paracasei LPC 09 DSM 24243, L. acidophilus LA02 DSM 21717 and L. acidophilus LA 07 DSM 24303.
11. The food composition or supplement product or medical device or pharmaceutical composition according to claim 6, wherein said fibre comprises fructo-oligosaccharides and inulin.
12. The food composition or supplement product or medical device or pharmaceutical composition according to claim 6, wherein the fructo-oligosaccharides and inulin are comprised in an amount from 3 to 15%, by weight.
13. The food composition or supplement product or medical device or pharmaceutical composition according to claim 6, wherein the fructo-oligosaccharides and inulin are comprised in an amount from 5 to 10% by weight.
US16/861,136 2011-05-09 2020-04-28 Bacterial strains capable of metabolizing oxalates Abandoned US20200325440A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/861,136 US20200325440A1 (en) 2011-05-09 2020-04-28 Bacterial strains capable of metabolizing oxalates

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2011A000791 2011-05-09
IT000791A ITMI20110791A1 (en) 2011-05-09 2011-05-09 BACTERIA OF BACTERIA ABLE TO METABOLIZE THE OXALATES.
PCT/IB2012/000895 WO2013050831A1 (en) 2011-05-09 2012-05-09 Bacterial strains capable of metabolizing oxalates
US201314116996A 2013-12-18 2013-12-18
US16/861,136 US20200325440A1 (en) 2011-05-09 2020-04-28 Bacterial strains capable of metabolizing oxalates

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14/116,996 Division US10982184B2 (en) 2011-05-09 2012-05-09 Bacterial strains capable of metabolizing oxalates
PCT/IB2012/000895 Division WO2013050831A1 (en) 2011-05-09 2012-05-09 Bacterial strains capable of metabolizing oxalates

Publications (1)

Publication Number Publication Date
US20200325440A1 true US20200325440A1 (en) 2020-10-15

Family

ID=44554462

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/116,996 Active US10982184B2 (en) 2011-05-09 2012-05-09 Bacterial strains capable of metabolizing oxalates
US16/861,136 Abandoned US20200325440A1 (en) 2011-05-09 2020-04-28 Bacterial strains capable of metabolizing oxalates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/116,996 Active US10982184B2 (en) 2011-05-09 2012-05-09 Bacterial strains capable of metabolizing oxalates

Country Status (14)

Country Link
US (2) US10982184B2 (en)
EP (1) EP2707477B1 (en)
JP (1) JP2014513977A (en)
CN (1) CN104039950B (en)
BR (1) BR112013028709B1 (en)
DK (1) DK2707477T3 (en)
ES (1) ES2690210T3 (en)
IT (1) ITMI20110791A1 (en)
LT (1) LT2707477T (en)
PL (1) PL2707477T3 (en)
PT (1) PT2707477T (en)
RU (1) RU2624033C2 (en)
SI (1) SI2707477T1 (en)
WO (1) WO2013050831A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US11446340B2 (en) 2011-05-09 2022-09-20 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1403661B1 (en) 2011-01-28 2013-10-31 Probiotical Spa EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
ITMI20110792A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF BACTERIA BELONGING TO THE BIFIDOBACTERIUM TYPE FOR USE IN THE TREATMENT OF HYPERCOLESTEROLEMIA.
ITRM20110477A1 (en) 2011-09-09 2013-03-10 Giovanni Mogna COMPOSITION INCLUDING N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTECT IN ASSOCIATION WITH PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF
ITMI20111718A1 (en) 2011-09-23 2013-03-24 Probiotical Spa A WATERPROOF MOISTURE AND OXYGEN MATERIAL FOR PACKAGING DIETARY, COSMETIC AND MEDICINAL PRODUCTS.
TWI481409B (en) * 2013-01-10 2015-04-21 Conmed Pharmaceutical & Bio Medical Corp A method for reducing uremic toxins by probiotic composition and the manufacturing method thereof
ITMI20130795A1 (en) * 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA AND / OR BIFIDOBACTERIES FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF BACTERIAL INFECTIONS AND / OR INFLAMMATIONS OF THE URINARY AND / OR PROSTATE TRACT THAT ARE THE CAUSE OF PROSTATITIS AND PROSTAT HYPERTROPHY
CN104546894B (en) * 2013-10-25 2017-11-28 田晶 Application of the inulin in the property hyperoxaluria of intestines source
IT201800005355A1 (en) * 2018-05-14 2019-11-14 Lactobacillus amylovorus SGL 14: probiotic activity and reduction of enteric oxalate
CN115500515A (en) * 2022-08-10 2022-12-23 华南理工大学 Application of lactobacillus plantarum in regulating intestinal flora

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819838A (en) 1970-08-04 1974-06-25 Bush Boake Allen Ltd Encapsulated flavoring composition
GB1363301A (en) 1971-07-12 1974-08-14 Ilford Ltd Supersensitising combination'
JPS53121949A (en) 1977-03-31 1978-10-24 Yakult Honsha Kk Production of drink and food containing bifidobacterium cells
DE2757370A1 (en) 1977-12-22 1979-07-05 Bayer Ag GAS-TIGHT PLASTIC-ALUMINUM COMPOSITE FILMS
CH637297A5 (en) 1978-12-05 1983-07-29 Nestle Sa MICROBALL COMPRISING A MICROORGANISM AND ITS MANUFACTURING METHOD.
JPS58152809A (en) 1982-03-05 1983-09-10 Eisai Co Ltd Stable foaming vaginal suppository
US4670272A (en) 1985-11-08 1987-06-02 Frito-Lay, Inc. Thermostable creme
DE3685955D1 (en) 1986-02-06 1992-08-13 Celgene Corp Biosynthese von heteropolysacchariden.
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
UA39965C2 (en) 1993-12-03 2001-07-16 Лайфор Леборетріз Лтд VIRUSIC, BACTERICIDAL AND DESTRUCTIVE SPERMATOSES VAGINAL PRODUCT AND VAGINAL SUPPOSITORY (OPTIONS)
RU2061040C1 (en) * 1994-05-23 1996-05-27 Акционерное общество "Русский йогурт" Strain of bacterium lactobacillus plantarum showing capability to decrease oxalate level and used for preparing preparations and foodstuffs for hyperoxaluria prophylaxis and treatment
EP0881905A1 (en) 1996-02-14 1998-12-09 The Procter & Gamble Company Urogenital and intestinal disorder compositions comprising a substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor
CN1211188A (en) 1996-02-14 1999-03-17 普罗克特和甘保尔公司 Urogenital and intestinal compositions
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
EP0845350A1 (en) 1996-11-29 1998-06-03 Alusuisse Technology & Management AG Cold formable laminated film
US6471992B1 (en) 1997-02-20 2002-10-29 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
FR2765078B1 (en) 1997-06-27 1999-09-17 Guyomarc H Nutrition Animale METHOD FOR IMPROVING THE EFFECTIVENESS OF A PROBIOTIC, PREPARATION OF FOOD ADDITIVES AND ANIMAL FEED CONTAINING IT
ATE314858T1 (en) 1998-04-01 2006-02-15 Ganeden Biotech Inc EXPERIENCE IN REDUCING CHOLESTEROL WITH BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS
EP0956858B1 (en) 1998-04-30 2001-10-31 Renata Maria Anna Cavaliere Vesely Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for treatment of vaginal infections
US6262019B1 (en) 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
KR20010101171A (en) 1998-12-11 2001-11-14 추후기재 Oral administration of lactobacillus for the treatment and prevention of urogenital infection
RU2150268C1 (en) 1998-12-25 2000-06-10 Быков Валерий Алексеевич Lactobacterium-containing suppository for treatment of patient with vagina dysbacteriosis
SE9900215D0 (en) 1999-01-26 1999-01-26 Pharmacia & Upjohn Ab New use
WO2000071138A2 (en) 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women
IT1309427B1 (en) * 1999-05-28 2002-01-23 Mendes S U R L DIETARY OR PHARMACEUTICAL COMPOSITION USEFUL FOR THE PREVENTION OR TREATMENT OF HYPEROXIDE AND ITS USE
DE19940592A1 (en) 1999-08-26 2001-03-08 Baensch Tetra Werke Portion packaging for gel feed
KR100357668B1 (en) 2000-02-19 2002-10-18 주식회사 한국야쿠르트 Lactobacillus acidophilus HY 2177, Lactobacillus casei HY 2743 having antibiotic activation for Helicobacter pylori and Lactobacillus product thereof
CA2416120A1 (en) 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
CN1234373C (en) 2000-09-28 2006-01-04 信谊药厂 Medicinal preparation containing lactobacillus acidophilus and preparation process thereof
RU2203946C1 (en) 2001-09-12 2003-05-10 Хачатрян Ашот Папикович Strain of bacterium lactobacillus acidophilus nv ep 317/402-x "balans-narine" used for preparing antigastritis and antiulcerous fermented-milk product
EP1444098B1 (en) 2001-09-24 2006-03-22 Dupont Teijin Films U.S. Limited Partnership Multi-layer polymeric film for packaging ovenable meals
US20050074442A1 (en) 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
RU2316586C2 (en) 2002-03-21 2008-02-10 Бифодан А/С PROBIOTIC STRAINS OF Lactobacillus (VARIANTS) AND THEIR USING
SE0201214D0 (en) 2002-04-23 2002-04-23 Jafar Mahdavi Multicultural fermented yogurt
GB0230042D0 (en) 2002-12-23 2003-01-29 Britannia Pharmaceuticals Ltd Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
US20040185032A1 (en) 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
AU2004228759B2 (en) 2003-04-09 2010-04-08 Dolhay Klinika Egeszsegugyi Kft. Sexual hygienic composition
US20050017013A1 (en) 2003-07-24 2005-01-27 Alberto Peisach Container for hot fill food packaging applications
US8871266B2 (en) 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
EP2033529B1 (en) 2003-10-24 2019-12-11 N.V. Nutricia Synbiotic composition for infants
DE50300325D1 (en) 2003-11-03 2005-03-31 Peter-Hansen Volkmann Vaginalpflegezusammensetzung
GB0330009D0 (en) 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
GB0405406D0 (en) 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
DE602004027120D1 (en) 2004-05-25 2010-06-24 Cognis Ip Man Gmbh Oral and / or topical preparations
US8168171B2 (en) 2004-08-05 2012-05-01 Probiotical S.P.A. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
US20060039973A1 (en) 2004-08-19 2006-02-23 Mary Aldritt Effervescent composition including water soluble dietary fiber
WO2006047680A2 (en) * 2004-10-27 2006-05-04 North Carolina State University Lactobacillus acidophilus nucleic acids and uses thereof
JP2006180836A (en) 2004-12-28 2006-07-13 Marudai Food Co Ltd Lactic acid bacterium controlling infection with food poisoning bacterium, fermentation product, food and medicine composition containing the same
RU2270248C1 (en) 2004-12-31 2006-02-20 Открытое акционерное общество "Лианозовский молочный комбинат" Bifidobacterium lactis 668 strain for production of fermented milk products, fermented and non-fermented foodstuffs, bioactive supplements, bacterial preparations, and cosmetics
WO2006082824A1 (en) 2005-02-03 2006-08-10 Nrl Pharma, Inc. Matrix-type enteric coated sustained release composition
ATE473636T1 (en) 2005-02-15 2010-07-15 Barry R Goldin FOODS CONTAINING PROBIOTIC AND ISOLATED BETA-GLUCAN AND METHOD OF USE THEREOF
TR201820329T4 (en) 2005-02-28 2019-01-21 Nutricia Nv Food Composition Containing Probiotics
KR100661032B1 (en) 2005-04-19 2006-12-22 주식회사한국야쿠르트 Composition for Improving Liver Function, Reduction of Serum Ethanol Level, and Antioxidation
RU2303058C2 (en) 2005-06-10 2007-07-20 ООО "Витбиомед-плюс" Agent "biobalans-k" for treatment of intestine infections complicated with dysbacteriosis
EP1733872A1 (en) 2005-06-15 2006-12-20 Alcan Technology & Management Ltd. Cold formable laminate
ES2335529T3 (en) 2005-07-21 2010-03-29 Kabushiki Kaisha Yakult Honsha NEW BACTERIA THAT BELONGS TO THE GENERO BIFIDOBACTERIUM AND USE OF THE SAME.
WO2007020884A1 (en) 2005-08-12 2007-02-22 Meiji Dairies Corporation BIFIDOBACTERIUM OR LACTIC ACID BACTERIUM HAVING EFFECT OF PREVENTING INFECTION VIA β-DEFENSIN AND FOOD/PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
EP1923065B1 (en) 2005-09-08 2010-12-01 Kabushiki Kaisha Yakult Honsha Cholesterol absorption inhibitor
EP1775117A1 (en) 2005-10-12 2007-04-18 Alcan Technology & Management Ltd. Cold formable laminate for the making of blister base portions
WO2007050656A2 (en) 2005-10-24 2007-05-03 Nestec S.A. Dietary fiber formulation and method of administration
DE102005062731A1 (en) 2005-12-22 2007-06-28 Organobalance Gmbh New Lactobacillus strains and their use
WO2007100765A2 (en) 2006-02-28 2007-09-07 Childrens Memorial Hospital Lysozyme-modified probiotic components and uses thereof
MY149913A (en) 2006-03-07 2013-10-31 Nestec Sa Synbiotic mixture
RU2318523C2 (en) 2006-03-13 2008-03-10 Лев Давидович Раснецов Antibacterial agent
EP2269465A1 (en) 2006-05-03 2011-01-05 Probiotical S.p.a. Compositions comprising Bifidobacterium adolescentis
ITMI20061841A1 (en) * 2006-09-27 2008-03-28 Mofin S R L MICROBIAL LIQUID CULTIVATIONS WITH HIGH STABILITY AND FERMENTATIVE ACTIVITY
JP4829349B2 (en) 2006-11-17 2011-12-07 エスセーアー・ハイジーン・プロダクツ・アーベー Sanitary tissue containing microbial inhibitory composition
ITMI20062286A1 (en) 2006-11-28 2008-05-29 Anidral Srl A COMPOSITION FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE PRINCIPLES IN GYNECOLOGICAL AND RECTAL AREA AS WELL AS ITS USES
US20080175899A1 (en) 2007-01-19 2008-07-24 Ross Mairi R Formulation for promoting sinus health in nasal cavities
US20080187628A1 (en) 2007-02-02 2008-08-07 Champion Melinda L Water-Soluble, Quick-Dissolve Flavor Tablets
ITMI20070452A1 (en) 2007-03-07 2008-09-08 Anidral Srl COMPRESSOR INCLUDING MICRO-ORGANISMS AND A COMBINATION OF EXCIPIENTS AND RELATIVE PRODUCTION PROCEDURE
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
PL210465B1 (en) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Composition of strains type Lactobacillus and application of the composition of strains type Lactobacillus
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
US20090175843A1 (en) 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
US20090180999A1 (en) 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition
US20090226548A1 (en) 2008-01-11 2009-09-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition
EE05340B1 (en) 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Lactobacillus plantarum Tensia DSM 21380 and its use as an antimicrobial and antihypertensive probiotic in the manufacture of a medicament and for the prolongation of food shelf-life and contamination of food
DE102008023952A1 (en) 2008-05-16 2009-12-03 Alcan Technology & Management Ag Packaging cover film, container, packaging and packaging product unit
US9232813B2 (en) 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
RU2373274C1 (en) 2008-07-15 2009-11-20 Федеральное Государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Bifidobacterium breve ov-12 strain, used for making bacterial preparations, bioligically active additives to food, fermented and unfermented food products, hygienic and cosmetic agents
CN102124097B (en) 2008-08-28 2013-11-06 科.汉森有限公司 Bacterial composition
US8137718B2 (en) 2008-09-19 2012-03-20 Mead Johnson Nutrition Company Probiotic infant products
US9283252B2 (en) 2008-09-30 2016-03-15 Meiji Co., Ltd. Lactic acid bacterium having high oxalic acid decomposition ability
US20100092240A1 (en) 2008-10-09 2010-04-15 Joseph Glasser Agricultural water retention and replenishment system
RU2388479C1 (en) 2008-11-26 2010-05-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ОрГМА Росздрава) Hypercholesterinemia correction method
KR101075557B1 (en) 2008-12-03 2011-10-20 씨제이제일제당 (주) Novel Lactobacillus plantarum and compositions comprising the same
EP2210505A1 (en) 2009-01-27 2010-07-28 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
EP2403510B1 (en) * 2009-03-05 2020-02-26 Probiotical S.p.A. Bacteria strains having a high anti-inflammatory activity
IT1400821B1 (en) 2009-03-09 2013-07-02 Probiotical Spa OIL SUSPENSION CONTAINING PROBIOTIC BACTERIA FOR PEDIATRIC USE
EP2248908A1 (en) 2009-05-05 2010-11-10 Eurolactis Group S.A. Probiotic microorganisms isolated from donkey milk
FI20095550A0 (en) 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginal delivery system
IT1397566B1 (en) 2009-05-27 2013-01-16 Probiotical Spa LACTOBACILLUS PENTOSUS MANUFACTURER OF BACTERIOCINES, FOOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND ITS USE
JP5873018B2 (en) 2009-07-27 2016-03-01 ネステク ソシエテ アノニム Nutritional composition comprising fiber and probiotics
WO2011012932A1 (en) 2009-07-30 2011-02-03 Compagnie Gervais Danone Use of coated sterol or stanol particles for the preparation of food compositions having a low fat content and being essentially emulsifier-free
WO2011044934A1 (en) 2009-10-14 2011-04-21 Probiotical S.P.A Probiotic bacteria strains enabling of hydrolyzing prebiotic fibers and symbiotic compositions thereof
IT1398553B1 (en) 2010-03-08 2013-03-01 Probiotical Spa COMPOSITION INCLUDING PROBIOTIC BACTERIA FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH THE ALTERATION OF THE IMMUNE SYSTEM.
EP2364712B1 (en) 2010-03-11 2013-03-06 Kloarys Investment Ltd Topical cosmetic or pharmaceutical composition comprising probiotic lactobacillus strains and use of same
UA107711C2 (en) 2010-06-28 2015-02-10 Probiotical Spa Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
IT1403661B1 (en) 2011-01-28 2013-10-31 Probiotical Spa EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
US20140065116A1 (en) 2011-03-17 2014-03-06 Giovanni Mogna Probiotic bacteria having antioxidant activity and use thereof
ITMI20110679A1 (en) 2011-04-20 2012-10-21 Giovanni Mogna COMPOSITION INCLUDING PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF GASTRICITY.
ITMI20110792A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF BACTERIA BELONGING TO THE BIFIDOBACTERIUM TYPE FOR USE IN THE TREATMENT OF HYPERCOLESTEROLEMIA.
ITMI20110793A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF PROBIOTIC BACTERIA AND SYNBIOTIC COMPOSITION CONTAINING THEMSELVES INTENDED FOR THE BABY FOOD.
ITMI20110791A1 (en) 2011-05-09 2012-11-10 Probiotical Spa BACTERIA OF BACTERIA ABLE TO METABOLIZE THE OXALATES.
ITRM20110477A1 (en) 2011-09-09 2013-03-10 Giovanni Mogna COMPOSITION INCLUDING N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTECT IN ASSOCIATION WITH PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF
ITRM20110475A1 (en) 2011-09-09 2013-03-10 Probiotical Spa BACTERIA OF LACTIC AND / OR BIFIED BACTERIA BACTERIA, OPTIONALLY ADDED TO N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTETTO, HAVING INHIBITION ACTIVITIES / REDUCTION OF THE GROWTH OF DIFFERENT E.COLI BIOTYPES, INCLUDING E.COLI O157: H7 E
ITMI20111718A1 (en) 2011-09-23 2013-03-24 Probiotical Spa A WATERPROOF MOISTURE AND OXYGEN MATERIAL FOR PACKAGING DIETARY, COSMETIC AND MEDICINAL PRODUCTS.
JP5665141B2 (en) 2012-09-12 2015-02-04 株式会社明治 Method for producing tromomi yogurt
ITMI20130794A1 (en) 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND CURATIVE TREATMENT OF BACTERIAL VAGINOSIS.
ITMI20130793A1 (en) 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US11446340B2 (en) 2011-05-09 2022-09-20 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis

Also Published As

Publication number Publication date
CN104039950A (en) 2014-09-10
BR112013028709B1 (en) 2020-12-22
RU2013148473A (en) 2015-06-20
JP2014513977A (en) 2014-06-19
EP2707477A1 (en) 2014-03-19
WO2013050831A1 (en) 2013-04-11
EP2707477B1 (en) 2018-07-25
US20140105874A1 (en) 2014-04-17
BR112013028709A2 (en) 2017-01-24
PT2707477T (en) 2018-11-05
PL2707477T3 (en) 2019-01-31
LT2707477T (en) 2018-11-12
ES2690210T3 (en) 2018-11-19
CN104039950B (en) 2016-05-04
SI2707477T1 (en) 2018-12-31
US10982184B2 (en) 2021-04-20
DK2707477T3 (en) 2018-10-29
WO2013050831A9 (en) 2013-12-19
RU2624033C2 (en) 2017-06-30
ITMI20110791A1 (en) 2012-11-10

Similar Documents

Publication Publication Date Title
US20200325440A1 (en) Bacterial strains capable of metabolizing oxalates
US11338002B2 (en) Use for treatment of clostridium difficile infections
CN112534043B (en) Lactobacillus paracasei strain and application thereof
CN108603162B (en) Novel lactic acid bacteria and compositions for preventing, ameliorating or treating degenerative brain diseases or cognitive dysfunction
US7186545B2 (en) Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom
Ocaña et al. Vaginal lactobacilli: self-and co-aggregating ability
Sirilun et al. Characterisation of non human origin probiotic Lactobacillus plantarum with cholesterol-lowering property
RU2567009C2 (en) Lactococcus lactis STRAIN FOR TREATMENT OR PREVENTION OF DIGESTION DISORDER AND THEREOF APPLICATION
JPS61109729A (en) Cholesterol lowering agent
EP2521769A1 (en) Lactobacilli with anti-oxidant action
WO2010058294A1 (en) Blood-cholesterol-lowering strain of lactobacillus delbrueckii
JPS62145026A (en) Anticarcinogenic agent
US10098916B2 (en) Strains of the genus Lactobacillus and use thereof
KR20150066772A (en) A novel lactic acid bacteria and composition for preventing or treating diarrhea of an infant comprising the same
KR100609779B1 (en) Lactic acid bacteria degrading alcohol and acetaldehyde
CN115484968A (en) Stimulation of growth of bifidobacteria in the intestinal tract
KR100232639B1 (en) Novel bifidobacterium breve korean type which inhibits harmful enzyme activity
TWI406665B (en) Medicinal composition including probiotic strain gm-080 for use in treatment of cardiac inflammation and apoptosis
KR102533469B1 (en) Composition for preventing or treating inflammatory bowel disease
Solís Pacheco et al. CPQ Nutrition (2018) 1: 6 Research Article
CN117286045A (en) Bifidobacterium longum subspecies longum KS2 and application thereof in preparation of anti-aging food and medicine
JPS61109728A (en) Drug for alleviating periodontosis

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROBIOTICAL S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOGNA, GIOVANNI;STROZZI, GIAN PAOLO;MOGNA, LUCA;REEL/FRAME:052909/0245

Effective date: 20131203

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION